Prosecution Insights
Last updated: November 04, 2026
Application No. 17/906,637

METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM

Final Rejection §103
Filed
Sep 19, 2022
Priority
Mar 20, 2020 — CN PCT/CN2020/080477 +2 more
Examiner
KIM, DANIELLE A
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Techfields Inc.
OA Round
4 (Final)
36%
Grant Probability
At Risk
5-6
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allowance Rate
37 granted / 102 resolved
-23.7% vs TC avg
Strong +52% interview lift
Without
With
+52.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
75 currently pending
Career history
187
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
68.4%
+28.4% vs TC avg
§102
6.2%
-33.8% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 102 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application was filed 19 September 2022 and is the national stage entry of PCT/CN2021/082173filed 22 March 2021. The Applicant claims priority to PCTCN2020080477 filed 20 March 2020. An English copy of the document has been provided. The effective filing date of the instant application is 20 March 2020. Examiner’s Note The Applicant's amendments and arguments filed 17 September 2026 are acknowledged and have been fully considered. The Examiner has re-weighed all the evidence of record. Rejections not reiterated from previous office actions are hereby withdrawn. The following rejections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. In the Applicant’s response, filed 17 September 2026, it is noted that no claims have been amended, canceled, or newly added. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 3-5, 8-12, 15, 19-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Yu (WO 2010065936 A1) in view of elvalabs.co. Regarding claim 1, Yu teaches methods for improving efficiency of delivery of drug compounds to a subject (entire teaching; para. 12; abs). The method and composition may comprise high penetration drugs in an aqueous and/or ethanol carrier (paras. 174, 175). The high penetration compound may be a peptide (para. 15), such as Leu-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH) (para. 20) and may be in its salt form (para. 84). A linker may link a functional unit to the drug through a bond, such as an ester bond (para. 23) with an isopropyl alkyl group (para. 87), which is interpreted as addressing Applicant’s election of H-Tyr-Gly-Gly-Phe-Leu-OCH(CH3)2.HCl. The compound and Applicant’s election is interpreted as a protonated amine group. The composition may be provided as a kit, typically as dry powders, that may be reconstituted later with solution (para. 128) before administration to a patient (para. 174). The components packaged as dry powders to be later reconstituted before administration is interpreted as being contained in separate containers. In one embodiment, the pH of one formulation is adjusted to 4-7 (para. 294). Regarding claim 3, the method and composition may comprise high penetration drugs in an aqueous and/or ethanol carrier (para. 174, 175). Regarding claim 4, the method and composition may comprise high penetration drugs in an aqueous and/or ethanol carrier (para. 174, 175). Regarding claim 5, the method and composition may comprise high penetration drugs in an aqueous and/or ethanol carrier (para. 174, 175). Regarding claim 9, the composition may further comprise pH adjusting and buffering agents, such as sodium acetate (para. 107). Regarding claim 10, the composition may further comprise pH adjusting and buffering agents, such as sodium acetate (para. 107). Regarding claim 11, the composition may further comprise pH adjusting and buffering agents, such as sodium acetate (para. 107). Regarding claim 12, in one embodiment, the pH of one formulation is adjusted to 4-7 (para. 294). Regarding claim 15, the amount of drug can be 0.0001-100% (para. 109). Regarding claim 19, the amount of drug can be 0.0001-100% (para. 109). The method and composition may comprise high penetration drugs in an aqueous and/or ethanol carrier (paras. 174, 175). The amount of ethanol in water may vary, such as 25% (para. 241-242) or 70% ethanol (para. 214). In one embodiment, the pH of one formulation is adjusted to 4-7 (para. 294). Regarding claim 20, A linker may link a functional unit to the drug through a bond, such as an ester bond (para. 23) with an isopropyl alkyl group (para. 87), which is interpreted as addressing Applicant’s election of H-Tyr-Gly-Gly-Phe-Leu-OCH(CH3)2.HCl. Regarding claim 21, the amount of drug can be 0.0001-100% (para. 109). The method and composition may comprise high penetration drugs in an aqueous and/or ethanol carrier (paras. 174, 175). The amount of ethanol in water may vary, such as 25% (para. 241-242) or 70% ethanol (para. 214). In one embodiment, the pH of one formulation is adjusted to 4-7 (para. 294). The composition may further comprise pH adjusting and buffering agents, such as sodium acetate (para. 107). Yu does not teach an exact combination of steps recited in claim 1. Yu does not teach administering the reconstituted peptide after more than a month in claim 1. Yu does not specifically teach storing the solution at a temperature of 2-8°C in claim 8. Elvalabs.co teaches that, in general, reconstituted peptides may be stored at 2-8°C and used within 4 weeks (pgs. 1-2). In regards to selecting the combination of packing and reconstituting the formulation comprising high penetration compound with a carrier in claim 1, “[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious.” KSR v. Teleflex, 127 S.Ct. 1727, 1740 (2007) (quoting Sakraida v. A.G.Pro, 425 U.S. 273, 282 (1976)). “When the question is whether a patent claiming the combination of elements of prior art is obvious,” the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR at 1741. The Court emphasized that “[a] person of ordinary skill is… a person of ordinary creativity, not an automaton.” Id. at 1742. Consistent with this reasoning, it would have been obvious to have selected various combinations of various disclosed ingredients from within a prior art disclosure, to arrive at compositions “yielding no more than one would expect from such an arrangement.” Yu teaches methods for improving efficiency of delivery of drug compounds that may comprise high penetration drugs in an aqueous and/or ethanol carrier, whereas the claimed invention is directed towards a method for improving the stability of a composition comprising a high penetration drug substance and pharmaceutically acceptable carrier. Since Yu teaches the individual components of the claimed composition, it is obvious for one of ordinary skill in the art to select the different combinations of ingredients to arrive at the claimed invention with a reasonable expectation of success. Since Yu does not specifically teach storing the solution at a temperature of 2-8°C in claim 8, one of ordinary skill in the art would have been motivated to use elvalabs.co’s teaching that peptide solutions may be stored at a temperature of 2-8°C with a reasonable expectation of success. A skilled artisan would have been led to combine the teachings since a peptide solution would likely be used shortly after reconstitution and elvalabs.co teaches that a temperature of 2-8°C for storage will provide optimal stability. In regards to the storage limitation of more than a month in claim 8, elvalabs.co teaches that, in general, reconstituted peptides may be stored in refrigerated conditions for 4 weeks (pgs. 1-2). That being said and in lieu of objective evidence of unexpected results, the storage time can be viewed as a variable that achieves the recognized result of successfully performing the method of using a composition comprising a high penetration drug substance, which a skilled artisan would have been easily motivated to modify and adjust based on the broad teachings of elvalabs.co. The optimum or workable range for the storage time can be accordingly characterized as routine optimization and experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration, such as unexpected results, that would render the optimized length of time as nonobvious. Response to Arguments Applicant's arguments filed 17 September 2026 have been fully considered but they are not persuasive. The Applicant argues that elvalabs.co clearly teaches that the optimal storage condition for reconstituted peptides is 4 weeks (Remarks, pg. 2). The Applicant further argues that there is no motivation to adjust the storage time beyond the 4-week period (Remarks, pg. 2). Applicant’s argument is not found persuasive. Elvalabs.co teaches that, in general, reconstituted peptides may be stored at 2-8°C and used within 4 weeks (pgs. 1-2). Elvalabs.co’s teaching is used as a general guideline that a skilled artisan would have motivated to adjust and optimize as a part of routine experimentation. There are several factors that a skilled artisan would have to consider to ensure proper storage conditions of the peptides. For example, the kind or chemical makeup of the peptides, the length of peptides, or reconstituted or dry powdered peptides. A skilled artisan would be motivated with a reasonable expectation of success to adjust or modify the storage time based on several different factors, and, therefore, the optimal storage time and conditions would vary (thepeptideindex.org, pg. 3). The Applicant argues that the high penetration drug substance of the present application can be stored for more than 1 month, such as more than 3 months or even more than 1 year (Remarks, pgs. 3-4). Applicant’s argument is not found persuasive. The data shown in the Tables and paragraphs referenced by the Applicant show the stability or purity of different compounds stored at room temperature (25°C) over the course of 30, 60, 90, 180, and 360 days. The instant claims recite a high penetration drug substance that comprises one or two protonated amine groups in its molecule, as well as a storage temperature of 2-8°C. Therefore, the data are not commensurate in scope with the claims and it is unclear how the results are unexpected or surprising when the conditions do not directly correspond to the instant claims. “For objective evidence of secondary considerations to be accorded substantial weight, its proponent must establish a nexus between the evidence and the merits of the claimed invention.” Wyers v. Master Lock Co., 616 F.3d 1231, 1246 [95 USPQ2d 1525] (Fed. Cir. 2010) (quotation omitted). Where the offered secondary consideration actually results from something other than what is both claimed and novel in the claim, there is no nexus to the merits of the claimed invention. Tokai Corp. v. Easton Enters., Inc., 632 F.3d 1358, 1369 [97 USPQ2d 1673] (Fed. Cir. 2011) (“If commercial success is due to an element in the prior art, no nexus exists.”); Ormco Corp., 463 F.3d at 1312 (“[I]f the feature that creates the commercial success was known in the prior art, the success is not pertinent.”); In re Woodruff, 919 F.2d 1575, 1578 [16 USPQ2d 1934] (Fed. Cir. 1990). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danielle Kim whose telephone number is (571)272-2035. The examiner can normally be reached M-F: 9-5 p.m. PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached at (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.A.K./Examiner, Art Unit 1613 /ANDREW S ROSENTHAL/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Show 2 earlier events
Dec 15, 2025
Non-Final Rejection mailed — §103
Mar 12, 2026
Response Filed
Apr 15, 2026
Final Rejection mailed — §103
Jun 10, 2026
Request for Continued Examination
Jun 11, 2026
Response after Non-Final Action
Jun 23, 2026
Non-Final Rejection mailed — §103
Sep 17, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778903
PHARMACEUTICAL COMPOSITION AND BREXPIPRAZOLE ORALLY SOLUABLE FILM
2y 10m to grant Granted Nov 03, 2026
Patent 12758485
INSTANT EFFECT EYE CREAM
4y 11m to grant Granted Oct 13, 2026
Patent 12734193
AMMONIUM CHLORIDE FORMULATION TO SUPPORT HUMAN NATURAL DEFENSE AGAINST VIRUSES
4y 9m to grant Granted Sep 15, 2026
Patent 12728081
SUNSCREEN FORMULATION
2y 7m to grant Granted Sep 08, 2026
Patent 12714671
CELL MEMBRANE LIPID-EXTRACTED NANOPARTICLES (CLENS) FOR SELECTIVE TARGETING, IMAGE ANALYSIS AND CANCER THERAPY
5y 7m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
36%
Grant Probability
88%
With Interview (+52.1%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 102 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month